Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GRACELL BIOTECHNOLOGIES INC.

(GRCL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
8.83(c) 6.38(c) 7.79(c) 7.09(c) 7.07(c) Last
3 021 823 977 467 17 553 477 1 552 175 278 483 Volume
-1.67% -27.75% +22.10% -8.99% -0.28% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,05 M - -
Net income 2021 -74,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -31,2x
Yield 2021 -
Sales 2022 0,03 M - -
Net income 2022 -121 M - -
Net Debt 2022 - - -
P/E ratio 2022 -19,8x
Yield 2022 -
Capitalization 477 M 477 M -
Capi. / Sales 2021 9 119x
Capi. / Sales 2022 14 318x
Nbr of Employees 202
Free-Float 100%
More Financials
Company
Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The Company is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less... 
Sector
Biotechnology & Medical Research
Calendar
12/11 | 05:30pmPresentation
More about the company
Ratings of Gracell Biotechnologies Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about GRACELL BIOTECHNOLOGIES INC.
11/24GRACELL BIOTECHNOLOGIES : Announces Senior Management Team Share Purchase Plan - Form 6-K
PU
11/23Gracell Biotechnologies Says Management Team Members to Buy Up to $2 Million ADSs; Stoc..
MT
11/22GRACELL BIOTECHNOLOGIES : Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD1..
PU
11/19Health Care Stocks Falling Ahead of Friday Close
MT
11/19Health Care Stocks Drifting Lower Despite Friday Strength for Biotechs
MT
11/19Wall Street Set for Mixed Open, Europe's COVID-19 Situation in Focus
MT
11/19Health Care Stocks Climb Pre-Bell Friday
MT
11/19Top Premarket Gainers
MT
11/19Gracell Gets FDA Orphan Designation for GC012F in Multiple Myeloma
DJ
11/19Gracell Biotechnologies CAR-T Cell Therapy for Multiple Myeloma Gets Orphan Drug Design..
MT
11/19Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD..
PR
11/19Gracell Biotechnologies Inc Grants FDA Orphan Drug Designation for FasTCAR-enabled BCMA..
CI
11/17Gracell Biotechnologies to Participate in Piper Sandler 33rd Annual Virtual Healthcare ..
GL
11/17Gracell Biotechnologies to Participate in Piper Sandler 33rd Annual Virtual Healthcare ..
GL
11/16GRACELL BIOTECHNOLOGIES : Reports Third Quarter 2021 Unaudited Financial Results and Provi..
PU
More news
News in other languages on GRACELL BIOTECHNOLOGIES INC.
11/23Gracell Biotechnologies déclare que les membres de l'équipe de direction achèteront jus..
11/19Les actions du secteur de la santé en baisse avant la clôture de vendredi
11/19Les actions du secteur de la santé à la baisse malgré le dynamisme des biotechs ce vend..
11/19Les actions du secteur de la santé grimpent avant la cloche de vendredi
11/19La thérapie cellulaire CAR-T de Gracell Biotechnologies pour le myélome multiple obtien..
More news
Analyst Recommendations on GRACELL BIOTECHNOLOGIES INC.
More recommendations
Chart GRACELL BIOTECHNOLOGIES INC.
Duration : Period :
Gracell Biotechnologies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRACELL BIOTECHNOLOGIES INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 7,07 $
Average target price 33,33 $
Spread / Average Target 371%
EPS Revisions
Managers and Directors
Wei Cao Chairman & Chief Executive Officer
Kevin Yili Xie Chief Financial Officer
Martina A. Sersch Chief Medical Officer
Jenny Ni Chief Technology Officer
Wendy Hayes Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GRACELL BIOTECHNOLOGIES INC.0.00%477
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431